



ASX ANNOUNCEMENT

29 May 2023

Notification under section 708A(5)(e) of the *Corporations Act 2001* (Cth)

ImpediMed Limited (ABN 65 089 705 144) (ASX: IPD) (**ImpediMed**) gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

ImpediMed has today issued a total of 153,846,154 fully paid ordinary shares (**New Shares**) at an issue price of \$0.13 per New Share to institutional and sophisticated investors pursuant to the placement announced on 19 May 2023.

ImpediMed advises that:

- a. the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- b. this notice is being given under section 708A(5)(e) of the Corporations Act;
- c. As at the date of this notice, ImpediMed has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to ImpediMed; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- d. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by ImpediMed under 708A(6)(e) of the Corporations Act.

For and on behalf of the Board.

Leanne Ralph
Company Secretary

Authorised for release by the Board of Directors of ImpediMed Limited.

Contact Details

Investor Relations Contact:

Hannah Howlett
WE Communications
T: +61 045 648 064
E: hhowlett@we-worldwide.com
E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.